^
    Back
    Association details:
    Biomarker:ALK R1209Q
    Cancer:Colon Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    Votrient (pazopanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Onco Targets Ther
    Title:

    A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

    Published date:
    05/07/2021
    Excerpt:
    This is a single institution, open-label, phase I dose-escalation study in patients with advanced malignancies (NCT01548144)....Out of 9 patients enrolled in this trial with either MET or ALK aberrations, one patient with colon cancer and ALK p.R1209Q mutation had a best response of PR (−33%)...
    DOI:
    10.2147/OTT.S291801
    Trial ID:
    NCT01548144